Does surgically resected small-cell lung cancer without lymph node involvement benefit from prophylactic cranial...

Area of Science:

• Oncology
• Radiotherapy
• Thoracic Surgery

Background:

• Prophylactic cranial irradiation (PCI) is used for surgically resected small-cell lung cancer (SCLC).
• Its benefit in patients without lymph node involvement (N0M0) is controversial.
• This study addresses the controversy with a larger sample size.

Purpose of the Study:

• To evaluate the efficacy of PCI in surgically resected SCLC patients with no lymph node involvement.
• To determine if PCI reduces the risk of cerebral recurrence in this specific patient group.
• To provide evidence for clinical guideline revisions regarding PCI in early-stage SCLC.

Main Methods:

• Retrospective review of 146 surgically resected SCLC patients (N0M0) from Shanghai Chest Hospital (2006-2017).
• Comparison of outcomes between 46 patients who received PCI and 100 patients who did not.
• Analysis of brain metastases, time to recurrence, overall survival, and disease-free survival.

Main Results:

• No significant difference in the incidence of brain metastases between PCI and no-PCI groups (10.9% vs 12.0%).
• No significant difference in time to recurrence (P = 0.798).
• No significant difference in overall survival (HR=0.84) or disease-free survival (HR=0.95).

Conclusions:

• PCI therapy is not supported for managing surgically resected SCLC patients with no lymph node involvement.
• PCI does not reduce the risk of cerebral recurrence in resected p-T1-2N0M0 SCLC.
• Current evidence suggests reconsidering PCI recommendations for this patient subgroup.